乙型肝炎病毒的复制再活化  

Reactivation of hepatitis B virus

作　　者：阮杰[1] 李海军[1] 孙殿兴[1] 

机构地区：[1]白求恩国际和平医院全军肝病中心,河北省石家庄市050082

出　　处：《世界华人消化杂志》2014年第7期927-932,共6页World Chinese Journal of Digestology

摘　　要：乙型肝炎病毒(hepatitis B virus,HBV)复制再活化是指非活动性或已治愈的HBV感染患者血清中HBV DNA再度出现或升高,这一现象常发生在应用化疗药物或者免疫抑制剂治疗期间或之后,然而大多数病例临床症状并不明显,直至发展为活动性肝炎时才被发现.一些随机对照试验建议通过口服抗病毒药物,可有效预防HBV复制再活化的发生.因此,接受化疗药物或者免疫抑制剂治疗的患者均应筛查是否有现症或者既往HBV感染,若乙型肝炎表面抗原阳性,就应该接受抗病毒药物治疗.Reactivation of hepatitis B is characterized by the abrupt recurrence or the rise of hepatitis B virus（HBV） DNA in the serum of patients with previously inactive or resolved HBV infection, which frequently occurs during or after cytotoxic chemotherapy or immunosuppressive therapy; however, most of these cases are subclinical and only detected until activated liver disease. Several randomized controlled trials have shown that HBV reactivation can be prevented by antiviral prophylaxis. Thus, patients who are to receive cytotoxic chemotherapy or immunosuppressive therapy should be screened for present and previous hepatitis B infection, and hepatitis B surface antigen positive patients should receive antiviral prophylaxis.

关 键 词：乙型肝炎病毒 化疗 免疫抑制剂 核苷类似物 

分 类 号：R512.62[医药卫生—内科学]